Swollen glands NHS
10.1016/j.ebiom.2023.104494 9 ChenM.WeiS.WuX.XiangZ.LiX.HeH.et al (2024)
Stable Gastric Pentadecapeptide BPC 157 in Trials for Inflammatory Bowel Disease (PL-10, PLD-116, PL 14736, Pliva) Current Pharmaceutical Design Comprehensive review of BPC 157 clinical development for inflammatory bowel disease including ulcerative colitis trials, demonstrating mucosal healing and anti-inflammatory effects across multiple organ systems

Accelerates wound, skin and tissue healing Support gut health and healthy gut lining GI protective properties, alleviation from ulcers, bowel issues, and Crohns disease Protects cells and improves cell survival with oxidative stress Improves blood flow to injured areas Relieves pain from injuries Regulates brain serotonin and dopamine functions, possibly helping with mood Cardioprotective attributes Enhances muscle recovery, enabling greater volume and training frequency Stimulate collagen synthesis, including anti-aging effects*** Contents: 3mg/mL | 5mL Vial Dose: Men: 20 - 40 units | Women: 10 - 20 units Protocol: Inject 200 mcg SubQ daily
Join our exclusive webinar to gain insights into the rapidly evolving landscape of GLP-1 therapies and the broader healthcare ecosystem